iTeos Therapeutics (ITOS) Revenue & Revenue Breakdown
iTeos Therapeutics Revenue Highlights
Latest Revenue (Y)
$12.60M
Latest Revenue (Q)
$35.00M
Main Segment (Y)
License and Service
iTeos Therapeutics Revenue by Period
iTeos Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $12.60M | -95.29% |
| 2022-12-31 | $267.63M | -22.38% |
| 2021-12-31 | $344.77M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
iTeos Therapeutics generated $12.60M in revenue during NA 2023, up -95.29% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
iTeos Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $35.00M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $-11.30M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $12.60M | -76.63% |
| 2022-12-31 | $53.91M | 176.62% |
| 2022-09-30 | $19.49M | -53.29% |
| 2022-06-30 | $41.72M | -72.65% |
| 2022-03-31 | $152.52M | -36.58% |
| 2021-12-31 | $240.50M | 130.65% |
| 2021-09-30 | $104.27M | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
iTeos Therapeutics generated $35.00M in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 277.89% compared to the same period a year ago.
iTeos Therapeutics Revenue Breakdown
iTeos Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| License and Service | $12.60M | $267.60M | - | - |
| License And Service | - | - | $344.80M | $3.40M |
iTeos Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | Jun 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Service | $35.00M | $12.60M | - | $12.60M | $18.00M | $12.60M | $53.90M | $19.50M | $41.70M | - | - | - | - |
| License And Service | - | - | - | - | - | - | - | - | - | $152.50M | $104.30M | $3.40M | $3.40M |
iTeos Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License and Service (100.00%).
iTeos Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | Jun 20 |
|---|---|---|---|---|---|---|---|---|
| License and Service | $12.60M | $53.90M | $19.50M | $41.70M | - | - | - | - |
| License And Service | - | - | - | - | $152.50M | $104.30M | $3.40M | $3.40M |
iTeos Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: License and Service (100.00%).
iTeos Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| VECT | VectivBio | $27.34M | $676.00K |
| TCRX | TScan Therapeutics | $21.05M | - |
| ITOS | iTeos Therapeutics | $12.60M | $35.00M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| DSGN | Design Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| ERAS | Erasca | - | - |
| ANNX | Annexon | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| SANA | Sana Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| MLTX | MoonLake Immunotherapeutics | - | - |